Drugs Xagena
Celgene, in agreement with the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMEA ) has informed Healthcare Professionals about the following new safety in ...
Celgene, in agreement with the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMEA ) has informed Healthcare Professionals about the following new safety ...
Elevations of liver enzymes occur in 1-10 patients out of every 100 treated with Lenalidomide ( Revlimid ) for multiple myeloma in clinical trials; the majority of these are non-serious. Serious ( pot ...
Patients treated with Thalidomide ( Thalidomide Celgene ) have an increased risk of haematological second primary malignancies ( acute myeloid leukaemia and myelodysplastic syndromes ).Healthcare prof ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use ( CHMP ) has recommended marketing authorisation for Pomalidomide Celgene ( Imnovid ) to treat patients with multiple mye ...
The European Commission ( EC ) has approved Revlimid ( Lenalidomide ) for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. The Revlimi ...
The Chemotherapy Clinical Reference Group ( CRG ) has reviewed drugs and drug indications for inclusion on the National cancer drugs fund list. The decision summaries record how each drug/drug indica ...
The FDA ( Food and Drug Administration ) has granted approval for Empliciti ( Elotuzumab ) in combination with two other therapies to treat people with multiple myeloma who have received one to three ...
The FDA ( Food and Drug Administration ) has granted approval for Ninlaro ( Ixazomib ) in combination with two other therapies to treat people with multiple myeloma who have received at least one prio ...
The European Commission has approved Empliciti ( Elotuzumab ) for the treatment of multiple myeloma as combination therapy with Revlimid ( Lenalidomide ) and Dexamethasone in patients who have receive ...
The FDA ( Food and Drug Administration ) has granted a Breakthrough Therapy Designation to the immunotherapy Darzalex ( Daratumumab ) in combination with Lenalidomide ( Revlimid ), an immunomodulatory ...
The European Commission ( EC ) has approved Revlimid ( Lenalidomide ) as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous ...
The FDA ( Food and Drug Administration ) has granted accelerated approval to Xpovio ( Selinexor ) in combination with Dexamethasone for adult patients with relapsed or refractory multiple myeloma ( RR ...
The European Commission ( EC ) has approved Empliciti ( Elotuzumab ) plus Pomalidomide and low-dose Dexamethasone ( EPd ) for the treatment of adult patients with relapsed and refractory multiple myel ...
The U.S. Food and Drug Administration ( FDA ) has approved Darzalex ( Daratumumab ) in combination with Kyprolis ( Carfilzomib ) and Dexamethasone ( DKd ) for the treatment of adult patients with rela ...
The FDA ( Food and Drug Administration ) has granted accelerated approval to Monjuvi ( Tafasitamab-cxix, Tafasitamab ), a CD19-directed cytolytic antibody, indicated in combination with Lenalidomide f ...
The FDA ( U.S. Food and Drug Administration ) has approved Sarclisa ( Isatuximab ) in combination with Carfilzomib and Dexamethasone ( Kd ), for the treatment of adult patients with relapsed or refrac ...
The European Commission ( EC ) has approved Sarclisa ( Isatuximab ) in combination with Pomalidomide and Dexamethasone ( Pom-Dex ) for the treatment of adult patients with relapsed and refractory mult ...
The European Commission ( EC ) has approved Sarclisa ( Isatuximab ) in combination with Carfilzomib and Dexamethasone ( Kd ) for the treatment of adult patients with relapsed multiple myeloma who have ...
The European Commission ( EC ) has granted conditional marketing authorization for Minjuvi ( Tafasitamab ) in combination with Lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult ...
The Food and Drug Administration ( FDA ) hasapproved Sarclisa ( Isatuximab-irfc; Isatuximab ) in combination with Pomalidomide and Dexamethasone for adult patients with multiple myeloma who have recei ...
